BALVERSA DIN 02493217
Status: Marketed
Holder: JANSSEN INC
Available to quote
Health Canada record
| Active ingredient(s) | ERDAFITINIB 3 MG |
|---|
| Dosage form | Tablet |
|---|
| Route | Oral |
|---|
| Schedule | PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L01EN01 ERDAFITINIB |
|---|
| Original market date | 09-Dec-2019 |
|---|
| Current status date | 09-Dec-2019 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Janssen Inc — licence 100239, currently licensed, last inspection rating C (2026-03-09).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ERDAFITINIB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02493225 | BALVERSA | JANSSEN INC | Tablet | ERDAFITINIB 4 MG | Marketed |
| 02493233 | BALVERSA | JANSSEN INC | Tablet | ERDAFITINIB 5 MG | Marketed |
| 02493241 | BALVERSA | JANSSEN INC | Tablet | ERDAFITINIB 4 MG | Approved |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 22821 | 2019-10-25 | New Drug Submission (NDS) | |
Request a quote for BALVERSA
How to read a Canadian DIN record